{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:26:07Z","timestamp":1783992367412,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH081234"],"award-info":[{"award-number":["R01-MH081234"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.schres.2020.03.053","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T07:07:20Z","timestamp":1586070440000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia"],"prefix":"10.1016","volume":"220","author":[{"given":"Paul A.","family":"Nakonezny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet C.","family":"Lindow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Scott","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin S.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Byerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.03.053_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"Br. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2020.03.053_bb0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.schres.2015.12.012","article-title":"A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia","volume":"170","author":"Alphs","year":"2016","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.053_bb0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.psc.2007.04.002","article-title":"Antipsychotic medication adherence in schizophrenia","volume":"30","author":"Byerly","year":"2007","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"10.1016\/j.schres.2020.03.053_bb0030","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/ps.2007.58.6.844","article-title":"Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia","volume":"58","author":"Byerly","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.03.053_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.schres.2007.12.470","article-title":"The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder","volume":"100","author":"Byerly","year":"2008","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2020.03.053_bb0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YCO.0000000000000160","article-title":"Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance","volume":"28","author":"Haddad","year":"2015","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance In Psychosis (TRRIP) working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.053_bb0055","first-page":"5","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"12","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry 64 Suppl"},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF01064966","article-title":"Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison","volume":"61","author":"Kay","year":"1990","journal-title":"Psychiatr Q"},{"issue":"8","key":"10.1016\/j.schres.2020.03.053_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archpsyc.1989.01810080041005","article-title":"The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance","volume":"46","author":"Kay","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.053_bb0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.149.4.439","article-title":"Significance of positive and negative syndromes in chronic schizophrenia","volume":"149","author":"Kay","year":"1986","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.03.053_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2020.03.053_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.schres.2020.03.053_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive And Negative Syndrome Scale (PANSS): rationale and standardisation","author":"Kay","year":"1989","journal-title":"Br J Psychiatry Suppl"},{"issue":"10","key":"10.1016\/j.schres.2020.03.053_bb0090","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.03.053_bb0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2020.03.053_bb0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"2 Suppl","key":"10.1016\/j.schres.2020.03.053_bb0105","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2020.03.053_bb0110","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"19","key":"10.1016\/j.schres.2020.03.053_bb0115","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.schres.2020.03.053_bb0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4088\/JCP.v65n0408","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update","volume":"65","author":"Miller","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.053_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0000000000001082","article-title":"Long-acting injectables versus oral antipsychotics: a retrospective bidirectional mirror-image study","volume":"39","author":"Miura","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2020.03.053_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psychres.2013.02.015","article-title":"The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia","volume":"208","author":"Nakonezny","year":"2013","journal-title":"Psychiatry Res."},{"issue":"9","key":"10.1016\/j.schres.2020.03.053_bb0135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":"Long-acting risperidone and oral antipsychotics in unstable schizophrenia","volume":"364","author":"Rosenheck","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.03.053_bb0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2020.03.053_bb0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1742-1241.2012.02918.x","article-title":"Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians\u2019 perceptions of adherence vs. pharmacy claims","volume":"66","author":"Stephenson","year":"2012","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.schres.2020.03.053_bb0150","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable Risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.053_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.pra.0000388626.98662.a0","article-title":"Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines","volume":"16","author":"Velligan","year":"2010","journal-title":"J. Psychiatr. Pract."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642030164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642030164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:38:47Z","timestamp":1760297927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642030164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":31,"alternative-id":["S092099642030164X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.03.053","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.03.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}